Ironwood to buy VectivBio in $1B all-cash deal to expand rare gastrointestinal pipeline

Kyle LaHucik

Senior Reporter

Ironwood Pharmaceuticals agreed to buy Swiss biotech VectivBio in an all-cash deal with an estimated aggregate consideration of about $1 billion, extending the “

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Ironwood to buy VectivBio in $1B all-cash deal to expand rare gastrointestinal pipeline

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Iron­wood to buy Vec­tivBio in $1B all-cash deal to ex­pand rare gas­troin­testi­nal pipeline

Senior Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Ironwood to buy VectivBio in $1B all-cash deal to expand rare gastrointestinal pipeline